Literature DB >> 5854304

Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B.

A Ahlberg.   

Abstract

Entities:  

Mesh：

Year:  1965        PMID： 5854304     DOI： 10.3109/ort.1965.36.suppl-77.01

Source DB:  PubMed          Journal:  Acta Orthop Scand Suppl        ISSN： 0300-8827


× No keyword cloud information.
  41 in total

1.  Prophylaxis in congenital coagulation disorders: past, present and future.

Authors:  Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

2.  Prophylaxis for adults with haemophilia: one size does not fit all.

Authors:  Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-04       Impact factor: 3.443

Review 3.  Clinical use of factor VIII and factor IX concentrates.

Authors:  Massimo Morfini; Antonio Coppola; Massimo Franchini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

4.  Target of prophylaxis in severe haemophilia: more than factor levels.

Authors:  Antonio Coppola; Massimo Franchini
Journal:  Blood Transfus       Date:  2012-12-21       Impact factor: 3.443

5.  The importance of genetic factors for the development of arthropathy: a longitudinal study of children and adolescents with haemophilia A.

Authors:  Edward D Gomperts; John Schwarz; Sharyne M Donfield; Alice E Lail; Jan Astermark; W Keith Hoots; Cheryl A Winkler; Erik Berntorp
Journal:  Thromb Haemost       Date:  2016-12-08       Impact factor: 5.249

Review 6.  Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future.

Authors:  Victor Jiménez-Yuste; Günter Auerswald; Gary Benson; Thierry Lambert; Massimo Morfini; Eduardo Remor; Silva Zupančić Salek
Journal:  Blood Transfus       Date:  2014-07       Impact factor: 3.443

7.  Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization.

Authors:  Alanna McEneny-King; Pierre Chelle; Gary Foster; Arun Keepanasseril; Alfonso Iorio; Andrea N Edginton
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-18       Impact factor: 2.745

Review 8.  Low Dose Prophylaxis in Hemophilia Care.

Authors:  Neeraj Sidharthan; Remya Sudevan
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-15       Impact factor: 0.900

9.  Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study.

Authors:  Ezio Zanon; Annarita Tagliaferri; Samantha Pasca; Cosimo P Ettorre; Lucia D Notarangelo; Chiara Biasioli; Anna B Aru; Marta Milan; Silvia Linari; Angiola Rocino; Fabio Gagliano; Giovanni Di Minno; Gabriella Gamba; Rita C Santoro; Piercarla Schinco; Marco Marietta; Axel Seuser; Sylvia von Mackensen
Journal:  Blood Transfus       Date:  2019-06-05       Impact factor: 3.443

10.  Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.

Authors:  S Björkman; V S Blanchette; K Fischer; M Oh; G Spotts; P Schroth; S Fritsch; L Patrone; B M Ewenstein; P W Collins
Journal:  J Thromb Haemost       Date:  2010-04       Impact factor: 5.824
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.